



PARAINFLUENZA IMMUNITY

Prepared By: Diane Meyer

IMMUNE RESPONSE/CORRELATES OF PROTECTION

Human parainfluenza virus infection induces humoral and cellular immune responses. The cellular response restricts virus replication and is important in clearing the initial infection, and neutralizing antibodies that target specific surface proteins confer long-term immunity.¹

- IgA helps prevent reinfection but is short-lived, and “two or more infections might be needed in order for mucosal IgA to persist long term.”¹

REINFECTION

According to the CDC, “people can get multiple HPIV infections in their lifetime.” Reinfection usually leads to only mild illness but can be severe in older adults and people who are immunocompromised.²

- Most children under 5 years of age have antibodies against HPIV-3, and approximately 75% have immunity against HPIV-1 and HPIV-2.²

INFECTION IN IMMUNOCOMPROMISED PEOPLE

Those most at risk for HPIV infections in the immunocompromised population include solid organ and hematopoietic stem cell transplant recipients.³

- One study found that 2.2% of bone marrow transplant patients were infected with HPIV (27 total individuals), with respiratory failure and death occurring in 6 of those patients. The authors concluded that “parainfluenza virus infection is associated with substantial morbidity in recipients of bone marrow transplants.”⁴
- Another study among heart and lung transplant patients found that, of those infected with HPIV, 82% developed signs of acute allograft rejection and 32% were found to have bronchiolitis obliterans.

REFERENCES

1. Schmidt AC, Schaap-Nutt A, Bartlett EJ, et al. Progress in the development of human parainfluenza virus vaccines. *Expert Rev Respir Med* 2011;5(4):515-526.
2. US Centers for Disease Control and Prevention. Human parainfluenza viruses (HPIVs): clinical overview. CDC website. Updated October 6, 2017. <https://www.cdc.gov/parainfluenza/hcp/clinical.html>. Accessed May 9, 2018.

Prepared as background material by the Johns Hopkins Center for Health Security
for the [Clade X](#) tabletop exercise



3. Falsey AR. Current management of parainfluenza pneumonitis in immunocompromised patients: a review. *Infect Drug Resist* 2012;5:121-127.
4. Wendt CH, Weisdorf DJ, Jordan MC, Balfour HH Jr, Hertz MI. Parainfluenza virus respiratory infection after bone marrow transplantation. *N Engl J Med* 1992;326(14):921-926.
5. Vilchez RA, McCurry K, Dauber J, et al. The epidemiology of parainfluenza virus infection in lung transplant recipients. *Clin Infect Dis* 2001;33(12):2004-2008.

Date: May 9, 2018